In contrast, the efficacy of MCA was not significantly different (1.14-fold) in the NCI-H460 and NCI-H460/MX20 cancer cells, demonstrated that ABCG2-overexpressing cell line did not confer resistance to MCA. Here, ABCG2 is linked to cancer.